Traditional Anticoagulants and Hair Loss: A Role for Direct Oral Anticoagulants? A Review of the Literature

被引:4
作者
Watras M.M. [1 ]
Patel J.P. [2 ,3 ]
Arya R. [2 ]
机构
[1] Pharmacy Department, King’s College Hospital, Denmark Hill, London
[2] King’s Thrombosis Centre, Department of Haematological Medicine, King’s College Hospital, London
[3] Institute of Pharmaceutical Science, King’s College London, London
关键词
Warfarin; International Normalize Ratio; Enoxaparin; Dabigatran; Alopecia;
D O I
10.1007/s40801-015-0056-z
中图分类号
学科分类号
摘要
Hair loss is associated with the anticoagulants heparin and warfarin. With the recent availability of direct oral anticoagulants (DOACs) it is of clinical interest to know if they are implicated with hair loss and/or whether they could be successfully prescribed for patients who suffer from coumarin- or heparin-related alopecia. Initially reports of heparin- and coumarin-associated alopecia available through PubMed and Medline were explored in order to establish the cause of this side effect. Currently there is a lack of unanimity on why anticoagulants cause alopecia. However, timing and presentation strongly suggest that telogen effluvium is part of the process. The observation that both heparins and coumarins cause a similar pattern of hair loss suggests a shared mechanism related to anticoagulant activity. To date, the World Health Organization has received 405 reports of DOAC-associated alopecia through their pharmacovigilance database VigiBase®. Additionally, real world registry data describes an alopecia incidence of 4.4 per 100 patient years in patients prescribed rivaroxaban and dabigatran. Further widespread clinical experience is required to ascertain if this is true, but early indications suggest that DOACs are implicated in hair loss and will not provide a suitable alternative for patients suffering from alopecia related to traditional anticoagulants. © 2016, The Author(s).
引用
收藏
页码:1 / 6
页数:5
相关论文
共 25 条
[1]  
Taylor D.M., Paton C., Kapur S., Prescribing guidelines in psychiatry, (2015)
[2]  
Tudhope G.R., Cohen H., Meikle R.W., Alopecia following treatment with dextran sulphate and other anticoagulant drugs, Br Med J., 1, 5078, pp. 1034-1037, (1958)
[3]  
Fischer R., Bircher J., Reich T., Falling of hair after anticoagulant therapy, Schweiz Med Wochenschr., 83, 22, pp. 509-511, (1953)
[4]  
Warfarin, Amdipharm Mercury Company Limited, (2014)
[5]  
Heidbuchel H., Verhamme P., Alings M., Antz M., Hacke W., Oldgren J., Et al., European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation, Europace., 15, 5, pp. 625-651, (2013)
[6]  
Kligman A.M., Pathologic dynamics of human hair loss, I. Telogen effuvium. Archives of dermatology., 83, pp. 175-198, (1961)
[7]  
Ioannides G., Alopecia: a pathologist’s view, Int J Dermatol., 21, 6, pp. 316-328, (1982)
[8]  
Rook A., Some chemical influences on hair growth and pigmentation, Br J Dermatol., 77, pp. 115-129, (1965)
[9]  
Pillans P.I., Woods D.J., Drug-associated alopecia, International journal of dermatology., 34, 3, pp. 149-158, (1995)
[10]  
Cornbleet T., Hoit L., Alopecia from coumarin, AMA Arch Derm., 75, 3, pp. 440-441, (1957)